Tharimmune (NASDAQ:THAR – Get Free Report) posted its quarterly earnings results on Tuesday. The company reported ($2.02) earnings per share for the quarter, Zacks reports.
Tharimmune Trading Down 2.8 %
Shares of Tharimmune stock traded down $0.04 during trading on Thursday, reaching $1.40. The company’s stock had a trading volume of 3,588 shares, compared to its average volume of 353,467. Tharimmune has a 52 week low of $1.28 and a 52 week high of $7.46. The business’s 50-day moving average price is $1.75 and its 200-day moving average price is $2.12.
Analysts Set New Price Targets
Several research firms have issued reports on THAR. Rodman & Renshaw assumed coverage on shares of Tharimmune in a research report on Friday, December 6th. They set a “buy” rating and a $17.00 price target on the stock. RODMAN&RENSHAW upgraded Tharimmune to a “strong-buy” rating in a report on Friday, December 6th.
About Tharimmune
Tharimmune, Inc, a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1).
Featured Stories
- Five stocks we like better than Tharimmune
- Buy P&G Now, Before It Sets A New All-Time High
- Top 3 Beverage Stocks Pouring Out Profits
- Top Stocks Investing in 5G Technology
- CarMax and Carvana: Steering the Used Car Market
- What is the Australian Securities Exchange (ASX)
- How China’s Recovery Could Boost These 3 Platinum Plays
Receive News & Ratings for Tharimmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tharimmune and related companies with MarketBeat.com's FREE daily email newsletter.
